CA3137095A1 - Bicyclic peptide ligands specific for ox40 - Google Patents

Bicyclic peptide ligands specific for ox40

Info

Publication number
CA3137095A1
CA3137095A1 CA3137095A CA3137095A CA3137095A1 CA 3137095 A1 CA3137095 A1 CA 3137095A1 CA 3137095 A CA3137095 A CA 3137095A CA 3137095 A CA3137095 A CA 3137095A CA 3137095 A1 CA3137095 A1 CA 3137095A1
Authority
CA
Canada
Prior art keywords
seq
referred
peptide
amino acids
loop sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3137095A
Other languages
English (en)
French (fr)
Inventor
Nicholas Keen
Kevin Mcdonnell
Tom Li Stephen
Liuhong CHEN
Helen HARRISON
Peter Park
Michael Skynner
Harvey CHE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of CA3137095A1 publication Critical patent/CA3137095A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3137095A 2019-05-09 2020-05-11 Bicyclic peptide ligands specific for ox40 Pending CA3137095A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845473P 2019-05-09 2019-05-09
US62/845,473 2019-05-09
PCT/GB2020/051144 WO2020225577A1 (en) 2019-05-09 2020-05-11 Bicyclic peptide ligands specific for ox40

Publications (1)

Publication Number Publication Date
CA3137095A1 true CA3137095A1 (en) 2020-11-12

Family

ID=70847426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3137095A Pending CA3137095A1 (en) 2019-05-09 2020-05-11 Bicyclic peptide ligands specific for ox40

Country Status (12)

Country Link
US (1) US11613560B2 (cg-RX-API-DMAC7.html)
EP (1) EP3965827A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022532134A (cg-RX-API-DMAC7.html)
KR (1) KR20220007098A (cg-RX-API-DMAC7.html)
CN (1) CN113811541A (cg-RX-API-DMAC7.html)
AU (1) AU2020269506A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022315A2 (cg-RX-API-DMAC7.html)
CA (1) CA3137095A1 (cg-RX-API-DMAC7.html)
IL (1) IL287881A (cg-RX-API-DMAC7.html)
MX (1) MX2021013669A (cg-RX-API-DMAC7.html)
SG (1) SG11202111606TA (cg-RX-API-DMAC7.html)
WO (1) WO2020225577A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
SI4464721T1 (sl) * 2019-10-03 2025-08-29 Bicycletx Limited Heterotandemski biciklični peptidni kompleksi
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
CA3206529A1 (en) * 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
JP2024504068A (ja) * 2021-01-08 2024-01-30 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
US12539335B2 (en) 2021-09-29 2026-02-03 Conjustar (Zhuhai) Biologics Co., Ltd. Tricyclic polypeptide conjugated drug and use thereof
CN114933638B (zh) * 2022-05-12 2024-07-26 厦门大学 特异性靶向cd28的多元环肽配体框架

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
US9828432B2 (en) * 2012-02-06 2017-11-28 Providence Health & Services—Oregon Cancer treatment and monitoring methods using OX40 agonists
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
PT3149025T (pt) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
MX2017016844A (es) * 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
BR112018071612A2 (pt) 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
GB201607827D0 (en) * 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
EP3559018A1 (en) 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
CA3095582A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
SI4464721T1 (sl) 2019-10-03 2025-08-29 Bicycletx Limited Heterotandemski biciklični peptidni kompleksi
CN114760988A (zh) 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)

Also Published As

Publication number Publication date
US20200354406A1 (en) 2020-11-12
MX2021013669A (es) 2021-12-10
CN113811541A (zh) 2021-12-17
WO2020225577A1 (en) 2020-11-12
BR112021022315A2 (pt) 2021-12-28
AU2020269506A1 (en) 2022-01-06
EP3965827A1 (en) 2022-03-16
KR20220007098A (ko) 2022-01-18
SG11202111606TA (en) 2021-11-29
JP2022532134A (ja) 2022-07-13
US11613560B2 (en) 2023-03-28
IL287881A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
US11613560B2 (en) Bicyclic peptide ligands specific for OX40
AU2019247795B2 (en) Heterotandem bicyclic peptide complexes
ES3033517T3 (en) Heterotandem bicyclic peptide complexes
AU2020322193B2 (en) Heterotandem bicyclic peptide complexes
CN113543813B (zh) Cd38特异性的双环肽配体
JP2024023291A (ja) 多量体二環式ペプチドリガンド
CN114787197A (zh) 修饰的多聚双环肽配体
EP3911743A1 (en) Bicyclic peptide ligands specific for caix
EP3911665A1 (en) Bicyclic peptide ligands specific for caix
EP3894008A1 (en) Bicyclic peptide ligands specific for psma
HK40123165A (en) Heterotandem bicyclic peptide complexes
HK40117689B (en) Heterotandem bicyclic peptide complexes
HK40117689A (en) Heterotandem bicyclic peptide complexes

Legal Events

Date Code Title Description
U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241113

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260221